Intravesical Therapy Evaluation
Intravesical Therapy Evaluation - Related Videos
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
0 Views •
Cited by 12 •
2012
Establishing an orthotopic bladder tumor model to evaluate antitumor effects of intravesically delivered saRNA and monitoring tumor growth by ultrasound and bioluminescent imaging.
07:34
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
0 Views •
Cited by 13 •
2012
Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection, and can be simulated by a surgical technique termed cecal ligation and puncture (CLP). Here we describe a method to use CLP-induced animal model to screen medicinal herbs for therapeutic agents.
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
0 Views •
Cited by 4 •
2016
Methods to evaluate the efficacy and toxicity of RNA molecules targeting post-integration steps of the HIV-1 replication cycle are described. These methods are useful for screening new molecules and optimizing the format of existing ones.
04:28
Modeling Orthotopic Bladder Tumor in Mouse Model: A Procedure for Intravesical Administration of Cancer Cells into Murine Bladder
0 Views •
2023
In this video, we describe the intravesical procedure of delivering cancer cells into the bladder of a mouse model. This procedure helps generate an orthotopic bladder tumor model that can be used to develop therapeutic strategies.
06:07
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
0 Views •
Cited by 4 •
2021
Myocardial gene therapy for ischemic heart disease holds great promise for future therapeutics. Here, we introduce a large animal model for evaluating the efficacy of gene therapy in the ischemic heart.
FAQs
The central evaluative question is whether local bladder exposure produces a measurable therapeutic effect without depending primarily on systemic exposure. Because the agent contacts the urothelium and tumor tissue directly, researchers can examine local response alongside safety and tolerability. This comparison helps distinguish a promising bladder-directed strategy from one whose benefits do not justify its observed treatment burden.
Retention is a key experimental condition because it determines how long the instilled agent can remain in contact with the urothelium and tumor tissue. Evaluation therefore considers dosing conditions together with treatment response and pharmacologic outcomes, rather than interpreting exposure as a simple yes-or-no event. Consistent retention conditions can make comparisons between treatment strategies more meaningful.
An evaluation is multidimensional: treatment response indicates whether the intervention is effective, while safety and tolerability describe its acceptability. Pharmacologic outcomes add information about how the agent behaves during local treatment. Considering these measures together prevents a response signal from being viewed in isolation and supports a more balanced comparison of candidate bladder cancer therapies.
A typical assessment follows a defined sequence: the agent is delivered through a catheter, retained in the bladder, and then evaluated using response, safety, tolerability, and pharmacologic measures. The workflow links the delivery conditions to the resulting observations. In both preclinical and clinical settings, this structure provides a common framework for examining local treatment performance.
Researchers apply Intravesical Therapy Evaluation when they need to compare bladder-directed treatment strategies or investigate dosing conditions for a drug or biological agent. Its value extends across preclinical and clinical cancer research, allowing local therapeutic effects to be examined in the setting where treatment is delivered. Findings can help prioritize approaches for further development.
Results can inform more than whether a treatment appears effective. By combining response data with safety, tolerability, and pharmacologic outcomes, investigators can identify strengths and limitations of a local intervention and assess how dosing conditions affect its evaluation. This evidence supports development of more precise bladder cancer treatments while keeping attention on both benefit and treatment experience.